BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€957.00ZpnffxXgqcnrzm

Boosting Our BioMerieux Fair Value Estimate to EUR 92 on Strong Q3; Shares Reasonably Priced

Narrow-moat BioMerieux had a strong third quarter that exceeded management’s earlier targets, though revenue is on track to meet our full-year estimates, which aligns with new guidance. We are increasing our fair value estimate to EUR 92 per share from EUR 87. Time value of money accounts for the bulk of the increase; we’ve also modeled slightly higher installed base growth of the flagship multipanel FilmArray system.

Sponsor Center